SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), a patent application for the treatment of dyskinesia was filed by Clearmind, a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems.The provisional patent application was filed with the United States Patent and Trademark Office. This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc’s Palmitoylethanolamide as a potential treatment for dyskinesia. “SciSparc has always placed great emphasis on developing a broad and robust intellectual property portfolio in order to protect its innovative therapies, so a new patent filing arising from our collaboration with Clearmind is exciting. Our collaboration with Clearmind continues to bear fruit and emphasizes our commitment to pioneering innovative treatments for conditions with unmet need,” stated SciSparc’s Chief Executive Officer, Oz Adler.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRC:
- SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
- SciSparc to commence its trial with SCI-210 in children with ASD
- SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
- SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
- SciSparc receives approval for Phase IIb trial of SCI-110 in Germany